Total Payments
$71,522
2022 Payments
$3,383
Companies
8
Transactions
62
Payment Breakdown by Category
Consulting$51,525 (72.0%)
Research$13,410 (18.7%)
Travel$3,052 (4.3%)
Other$3,000 (4.2%)
Food & Beverage$534.96 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $51,525 | 35 | 72.0% |
| Unspecified | $13,410 | 4 | 18.7% |
| Travel and Lodging | $3,052 | 9 | 4.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,000 | 1 | 4.2% |
| Food and Beverage | $534.96 | 13 | 0.7% |
Payments by Type
General
$58,112
58 transactions
Research
$13,410
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $44,295 | 37 | $0 (2022) |
| AstraZeneca UK Limited | $13,410 | 4 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $4,674 | 7 | $0 (2017) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $4,578 | 8 | $0 (2017) |
| Sage Therapeutics, Inc. | $4,400 | 2 | $0 (2021) |
| Zimmer Biomet Holdings, Inc. | $107.79 | 1 | $0 (2018) |
| Kerecis Limited | $35.36 | 2 | $0 (2022) |
| AbbVie Inc. | $22.15 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $3,383 | 3 | AstraZeneca Pharmaceuticals LP ($3,375) |
| 2021 | $9,849 | 6 | AstraZeneca Pharmaceuticals LP ($5,400) |
| 2020 | $12,150 | 15 | AstraZeneca Pharmaceuticals LP ($12,150) |
| 2019 | $16,050 | 8 | AstraZeneca Pharmaceuticals LP ($14,700) |
| 2018 | $16,338 | 14 | AstraZeneca Pharmaceuticals LP ($8,670) |
| 2017 | $13,752 | 16 | Merck Sharp & Dohme Corporation ($4,674) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/26/2022 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 Marigen, Kerecis Omega3 GraftGuide | Food and Beverage | Cash or cash equivalent | $8.48 | General |
| Category: Wound Care | ||||||
| 09/08/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 04/01/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 12/01/2021 | Kerecis Limited | Kerecis Omega3 Wound (Device), Kerecis Omega3 Surgibind, Kerecis Omega3 GraftGuide | Food and Beverage | Cash or cash equivalent | $26.88 | General |
| Category: Wound Care | ||||||
| 10/08/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 09/16/2021 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 05/13/2021 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 04/28/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: NEUROSCIENCE | ||||||
| 03/19/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 10/15/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 08/02/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 07/11/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 06/11/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 06/11/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 06/11/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 06/11/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 05/22/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 05/22/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 05/22/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 05/22/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| 04/03/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 04/03/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 04/03/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 04/03/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 11/26/2019 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $8,850.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| High dose ICS LABA 2ndController Study SIROCCO | AstraZeneca UK Limited | $12,060 | 3 |
| A Multicentre Randomized Double blind Parallel Group Placebocontrolled Phase III Efficacy and Safety Study of Benralizumab MEDI 563 Added to High dose Inhaled Corticosteroid Plus Long acting 2 Agonist in Patients with Uncontrolled Asthma CALIMA | AstraZeneca UK Limited | $1,350 | 1 |
About Dr. Michael Holtzman, MD
Dr. Michael Holtzman, MD is a Pulmonary Disease healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548288228.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Holtzman, MD has received a total of $71,522 in payments from pharmaceutical and medical device companies, with $3,383 received in 2022. These payments were reported across 62 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($51,525).
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Saint Louis, MO
- Active Since 07/18/2006
- Last Updated 04/17/2025
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1548288228
Products in Payments
- FASENRA (Drug) $8,910
- MDN (Device) $107.79
- Kerecis Omega3 Wound (Device) $26.88
- VRAYLAR (Drug) $22.15
- Kerecis Omega3 SurgiClose (Device) $8.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Saint Louis
Joseph Ojile, M.d, M.D
Pulmonary Disease — Payments: $978,724
Pulmonary Disease $978,724
Dr. Alexander Chen, Md, MD
Pulmonary Disease — Payments: $859,735
Pulmonary Disease $859,735
Dr. Derek Byers, Md, MD
Pulmonary Disease — Payments: $835,202
Pulmonary Disease $835,202
Dr. Marin Kollef, Md, MD
Pulmonary Disease — Payments: $588,781
Pulmonary Disease $588,781
Dr. Praveen Chenna, Md, MD
Pulmonary Disease — Payments: $265,830
Pulmonary Disease $265,830
Dr. Murali Chakinala, Md, MD
Pulmonary Disease — Payments: $211,522
Pulmonary Disease $211,522